Similar articles

• Monitoring guidelines for methotrexate-treated rheumatoid arthritis patients: comment on the article by Yazici et al.

  Alarcón GS, Kremer J, Weinblatt M. Alarcón GS, et al. Arthritis Rheum. 2004 Aug;50(8):2710; author reply 2710-1. doi: 10.1002/art.20318. Arthritis Rheum. 2004. PMID: 15334490 No abstract available.
• Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al.

  Morgan SL, Baggott JE, Alarcón GS. Morgan SL, et al. Arthritis Rheum. 2006 May;54(5):1708-9; author reply 1709-10. doi: 10.1002/art.21801. Arthritis Rheum. 2006. PMID: 16646062 No abstract available.
• Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al.

  Riksen NP, Rongen GA, Smits P, van Riel P, Barrera P. Riksen NP, et al. Arthritis Rheum. 2007 Feb;56(2):694; author reply 694-5. doi: 10.1002/art.22397. Arthritis Rheum. 2007. PMID: 17265507 No abstract available.
• The mechanism of action of methotrexate in rheumatoid arthritis: the search continues.

  Kremer JM. Kremer JM. J Rheumatol. 1994 Jan;21(1):1-5. J Rheumatol. 1994. PMID: 8151560 Review. No abstract available.
• Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis.

  Ranganathan P, McLeod HL. Ranganathan P, et al. Arthritis Rheum. 2006 May;54(5):1366-77. doi: 10.1002/art.21762. Arthritis Rheum. 2006. PMID: 16645965 Review. No abstract available.